Adams Respiratory Therapeutics Inc

Adams Respiratory Therapeutics — Investor Presentation (April 2007)

60 slides from Adams Respiratory Therapeutics's investor presentation, Apr 4, 2007

  1. Slide 1: New OTC Products Review

    Slide 1: New OTC Products Review

    Bob Casale Chief Operating Officer New OTC Products Review April 4, 2007

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor This presentation contains certain "forward-looking" statements. These statements are based on the current estimates and assumptions of the management of Adams Respiratory Therapeutics, Inc. ("Adams") as of the date of this presentation and are subject to uncertainty and changes in circu

  3. Slide 3: Total CCAS Category Dollar Sales Trend 2002-2006

    Slide 3: Total CCAS Category Dollar Sales Trend 2002-2006

    Total CCAS Category Dollar Sales Trend ($ MM) 2002-2006 4 Year CAGR 4 Year CAGR Category +8.4% Cough Syrup/Sore Throat +1.5% CAS Liquids/ Powders +0.2% CAS Tablets/ Packets +13% Source: Information Resources, Inc. (IRI), U.S. Food/Drug/Mass (FDMx) , 2002-2006. 2,159 2,715 2,602 2,972 2,986 Category

  4. Slide 4: Total CCAS Category Growth Brands - Dollar Sales Change

    Slide 4: Total CCAS Category Growth Brands - Dollar Sales Change

    $223 $10 $72 $305 All other Brands Delsym Mucinex Total CCAS Growth Brands Of the $305MM in CCAS growth brands this past year, Adams contributed $82MM- more than a quarter of the total. Source: IRI, U.S. FDMx, 52 weeks ended 2/25/07. Dollar Sales Chg VYA ($MM) Total CCAS Category Growth Brands - Dol

  5. Slide 5: CCAS Category Major Brands Performance

    Slide 5: CCAS Category Major Brands Performance

    CCAS Category Major Brands Performance $ % Chg VYA $ Share Chg Vs. VYA +62.1 11.0 +3.5 +50.8 10.2 +2.7 +1.1 6.8 -0.6 +0.2 6.7 -0.7 +12.0 6.1 0.1 -4.7 5.0 -0.8 +20.2 4.7 +0.3 -5.9 3.9 -0.2 +23.8 3.7 +0.4 +10.6 2.9 +0.0 61.8 2.3 +0.7 Source: IRI, U.S. FDMx, 12 weeks ended 2/25/07. $ Sales (MM) (r) (r)

  6. Slide 6: CCAS Brands Productivity Rank - $ Sales per SKU

    Slide 6: CCAS Brands Productivity Rank - $ Sales per SKU

    CCAS Brands Top 10 Productivity Rank - $ Sales per SKU Top 10 Productivity Rank - $ Sales per SKU Top 10 Productivity Rank - $ Sales per SKU Avg # SKU's carried Dollar Sales Rank 9 2 5 7 3 14 4 12 14 3 15 5 15 6 33 1 11 9 21 4 Source: IRI, U.S. FDMx, 12 weeks ended 2/25/07 Note: Avg # SKU's is for t

  7. Slide 7: Adams is a major player in the total CCAS category

    Slide 7: Adams is a major player in the total CCAS category

    Source: IRI U.S. FDMx, 52 weeks ended 7/2/06 and projection for 52 weeks ending 7/1/07. Mucinex(r) Mucinex(r) DM Mucinex(r) D Mucinex(r) Children's Liquids Mucinex(r) Children's Mini-Melts Delsym(r) 3.7 3.2 1.1 0.4 0.6 10.7% total 0.7 1.7 4.9 2.1 0.6 6.6% total FY 2006 FY 2007 Projected Adams is a m

  8. Slide 8: Fiscal 2007 New Products

    Slide 8: Fiscal 2007 New Products

    Fiscal 2007 New Products Fiscal 2007 Fiscal 2006

  9. Slide 9: Mucinex Core Equity

    Slide 9: Mucinex Core Equity

    Mucinex Core Equity Mucinex = Mucus Out

  10. Slide 10: Loyal Consumer Base

    Slide 10: Loyal Consumer Base

    Loyal Consumer Base Of the consumers who use Mucinex... ~90% intend to buy it again ~30% try more than one type of Mucinex ~70% actually plan their purchase ~50% would rather make an additional trip to another store if their store did not have Mucinex Source: Proprietary on-line research conducted 1

  11. Slide 11: Mucinex Advertising Awareness High

    Slide 11: Mucinex Advertising Awareness High

    Mucinex Advertising Awareness High 51% 38% Advertising Awareness Mucinex ranks # 2; only Nyquil(r) higher at 55%. Ahead of Claritin(r) (44%) - despite 2x Mucinex spending during cough/cold season Surpasses both Robitussin(r) and Tylenol(r) - 33% Far exceeds level of other new brands - Airborne(r) (2

  12. Slide 12: Ad Awareness the Key Driver of Overall Awareness

    Slide 12: Ad Awareness the Key Driver of Overall Awareness

    Ad Awareness the Key Driver of Overall awareness of Mucinex 69% 78% Brand Awareness Mucinex brand awareness of 78% is exceptional when compared to that of more established brands: Claritin(r) - 87%; Tylenol(r)/Robitussin(r)/Nyquil(r) - 97-99% Far exceeds the level achieved by other new brands: Airbo

  13. Slide 13: Strong Professional Following

    Slide 13: Strong Professional Following

    1. Pharmacy Times, 2007 OTC Survey of Pharmacists Recommendations conducted 10/06. 2. Proprietary Physician Tracking Study conducted 12/06. Strong Professional Following In a few short years, Mucinex has... Become #1 pharmacist recommended adult expectorant1 Achieved the highest satisfaction rate am

  14. Slide 14: Mucinex Patient Satisfaction and Symptom Relief

    Slide 14: Mucinex Patient Satisfaction and Symptom Relief

    90%+ of patients were pleased with Mucinex were pleased with Mucinex were pleased with Mucinex One week of treatment with Mucinex significantly improved all mucus-related symptoms Symptom Relief 100% 0 100% # of Patients COUGH EXCESS MUCUS NASAL CONGESTION THICK MUCUS CHEST CONGESTION 75.1 68.7 67.8

  15. Slide 15: Consumer/Professional: Working Together to Build Trial & Conversion

    Slide 15: Consumer/Professional: Working Together to Build Trial & Conversion

    Consumer Advertising Professional Detailing Generates Consumer Awareness Generates Professional Recommendations Trial Purchase Satisfied Consumer Consumer/Professional: Working Together to Build Trial & Conversion

  16. Slide 16: Top Three Influencers of Mucinex Trial

    Slide 16: Top Three Influencers of Mucinex Trial

    Top Three Influencers of Mucinex Trial Recommendations by healthcare professionals 49% Friend/family recommendation 31% TV advertising 28% Source: Proprietary consumer tracking study conducted 12/06.

  17. Slide 17: Mucinex Adult Products Today

    Slide 17: Mucinex Adult Products Today

    Mucinex Adult Products Today 600 mg. guaifenesin-based 12 hour tablets Leading position in cough, cold and sinus segments Highly productive franchise

  18. Slide 18: Introducing...The Next Major Addition to the Mucinex Franchise

    Slide 18: Introducing...The Next Major Addition to the Mucinex Franchise

    Introducing...The Next Major Addition to the Mucinex Franchise Addition to the Mucinex Franchise Addition to the Mucinex Franchise

  19. Slide 19: Mucinex Adult Products Where We Are Going

    Slide 19: Mucinex Adult Products Where We Are Going

    Address consumer that demands maximum strength treatment options Expand franchise across any Upper Respiratory segment, Rx or OTC, that delivers consumer value through innovation and stays true to "mucus out" equity Mucinex Adult Products Where We Are Going OTC Rx

  20. Slide 20: Market Research Confirms Need for Maximum Strength Product

    Slide 20: Market Research Confirms Need for Maximum Strength Product

    Market Research Confirms Need for Maximum Strength Product Key Findings* Majority of respondents were very interested in buying Maximum Strength Mucinex Majority prefer one tablet dose of Maximum Strength Mucinex Research also indicates that Mucinex franchise revenue should increase significantly wi

  21. Slide 21: Maximum Strength Mucinex Strengthens the Mucinex Franchise

    Slide 21: Maximum Strength Mucinex Strengthens the Mucinex Franchise

    Maximum Strength Mucinex Strengthens the Mucinex Franchise Source: Maximum Strength Mucinex Discrete Choice Study, 3/07. Definitely / Probably "would buy" 58% 83% Total Category Users Mucinex Users Strong interest in Maximum Strength Mucinex among both non-users and current users Based upon key attr

  22. Slide 22: Mirrors Existing Consumer Behavior

    Slide 22: Mirrors Existing Consumer Behavior

    Mirrors Existing Consumer Behavior Preferred Mucinex Dosage for Mucinex and Non-Mucinex Users Source: Maximum Strength Mucinex Discrete Choice Study, 3/07. Source: Maximum Strength Mucinex Discrete Choice Study, 3/07. 63% of current Mucinex users take only one tablet per dose Majority of consumers w

  23. Slide 23: 46% of Volume Comes From Competitive Brands

    Slide 23: 46% of Volume Comes From Competitive Brands

    46% of the Volume for Maximum Strength Mucinex Comes From Competitive Brands 54% of the volume for Maximum Strength should come from current Mucinex products Most vulnerable competitors include: Vicks Nyquil(r)/Dayquil(r), 11%; Robitussin(r), 9%; Tylenol(r), 6% Source: Maximum Strength Mucinex Discr

  24. Slide 24: Strong Potential for Maximum Strength

    Slide 24: Strong Potential for Maximum Strength

    Strong Potential for Maximum Strength In Year 1, Maximum Strength Mucinex is projected to achieve between $50MM and $70MM in consumption Approximately 40% of Maximum Strength Mucinex dollars expected to be incremental Total Adult Mucinex franchise is expected to grow in excess of 20% Source: Maximum

  25. Slide 25: Maximum Strength Potential

    Slide 25: Maximum Strength Potential

    Maximum Strength Potential Research indicates that over time, Maximum Strength Mucinex may represent 60% of Mucinex franchise sales Assumes: Full distribution Continued support Acceptability of tablet size Source: Maximum Strength Mucinex Discrete Choice Study, 3/07.

  26. Slide 26: Marketing Maximum Strength Mucinex

    Slide 26: Marketing Maximum Strength Mucinex

    Marketing Maximum Strength Mucinex Dedicated TV commercial Focused Professional efforts targeted to doctors and pharmacists

  27. Slide 27: Children's Mucinex Line

    Slide 27: Children's Mucinex Line

    Children's Mucinex Line

  28. Slide 28: Children's Mucinex and Delsym expanded the category

    Slide 28: Children's Mucinex and Delsym expanded the category

    Children's Mucinex and Delsym expanded the category Children's CCAS Category Major Brands Performance Major Brands Performance Major Brands Performance $ % VYA $ Share Chg VYA +61.6 19.5 +3.4 +22.4 19.3 -1.7 +29.0 12.1 +0.4 n/a 8.3 8.3 +22.9 6.9 -0.6 -9.3 6.0 -2.8 +63.9 5.8 +1.1 -43.0 4.7 -6.3 +16.4

  29. Slide 29: Children's CCAS Brands Productivity Rank

    Slide 29: Children's CCAS Brands Productivity Rank

    Children's CCAS Brands Productivity Rank - $ Sales per SKU Avg # SKU's carried Dollar Sales Rank 6.1 1 1.5 7 3.3 4 5.0 3 10.1 2 3.8 5 3.7 8 5.0 6 1.6 10 2.4 9 $ Sales per SKU (MM) Source: IRI, U.S. FDMx, 12 weeks ending 2/25/07. (r) (r) (r) (r) (r) (r) (r) (r)

  30. Slide 30: Children's Mucinex Products Today

    Slide 30: Children's Mucinex Products Today

    Children's Mucinex Products Today Immediate-release guaifenesin-based line Innovative form addressing consumer needs Highly productive line poised for a top place within segment

  31. Slide 31: Introducing...The New Additions to the Children's Mucinex Line

    Slide 31: Introducing...The New Additions to the Children's Mucinex Line

    Introducing...The New Additions to the Children's Mucinex Line

  32. Slide 32: Two New Indications

    Slide 32: Two New Indications

    Two New Indications Adding New Indications to the Children's Line 100 mg guaifenesin/ 5 mg dextromethorphan HBr Orange Creme flavor Congestion and cough "Cough" for Mini-Melts 100 mg guaifenesin/ 2.5 mg phenylephrine/5 ml Mixed Berry flavor Nasal congestion & Cough "Cold" for Liquids

  33. Slide 33: Children's Mucinex Products Where We Are Going

    Slide 33: Children's Mucinex Products Where We Are Going

    Parents' product of choice for cough/cold relief for their children Technology-based point of difference Address convenience, compliance and efficacy needs Future introductions may not be limited to monographed OTC products Children's Mucinex Products Where We Are Going

  34. Slide 34: Children's Mucinex Meets Consumer Needs

    Slide 34: Children's Mucinex Meets Consumer Needs

    Children's Mucinex Meets Consumer Needs Mini-Melt Cough and Liquid Cold formulations Cough is viewed as most disruptive symptom by parents* "Good taste" and "easy to take" are critical to compliance according to both moms and pediatricians* Cold indication represents multi-symptom relief Children's

  35. Slide 35: Children's Mucinex Marketing Support

    Slide 35: Children's Mucinex Marketing Support

    Children's Mucinex Marketing Support Dedicated TV commercial Focused Professional efforts targeted to pediatricians

  36. Slide 36: Mucinex equity travels to a new market segment

    Slide 36: Mucinex equity travels to a new market segment

    Mucinex equity travels to a new market segment

  37. Slide 37: Strong Equity Relevant To Consumers

    Slide 37: Strong Equity Relevant To Consumers

    Strong Equity Relevant To Consumers Established brand equity "Mucinex In, Mucus out.(tm)" Successful launch in children's segment indicates opportunity to extend Mucinex brand name All 4 SKUs rank among the top twenty-five; outselling established competitive liquids1 1IRI, FDMx, 4 weeks ended 2/25/0

  38. Slide 38: Introducing...

    Slide 38: Introducing...

    Introducing... Seis seca rele iin emery Sosubce tes a _| a fs Concentrated Vapor Technology to ea J RESEIRATOR’ P\ Ow 38

  39. Slide 39: Mucinex Nasal Sprays Unique Benefits

    Slide 39: Mucinex Nasal Sprays Unique Benefits

    Mucinex Nasal Sprays Unique Benefits Full Force Effective nasal decongestant "Sensory signal" lets consumer know it is working "12 Hour Concentrated Vapor Technology" Moisture Smart Effective nasal decongestant Specially formulated to soothe irritated nasal membranes "12 Hour Membrane Hydration Tech

  40. Slide 40: Mucinex Nasal Sprays will compete in a $370MM OTC category

    Slide 40: Mucinex Nasal Sprays will compete in a $370MM OTC category

    Mucinex Nasal Sprays will compete in a $370MM OTC category Nearly a 50/50 split between medicated and non-medicated segments. IRI, FDMx 52 Wks Ended 12/31/06 $ Sales (MM) % Chg VYA Total Nasal Category $370 +7 Non-Medicated Sprays/Drops/Inhalers 194 +12 Medicated Sprays/Drops 177 +4 Mucinex Nasal Sp

  41. Slide 41: Mucinex Should Build Nasal Spray Category

    Slide 41: Mucinex Should Build Nasal Spray Category

    Proprietary research indicates that 64% of current Mucinex adult users who do not use other nasal sprays intend to purchase Mucinex Nasal Spray Importantly, these users will add this new product to their treatment regimen Mucinex Should Build Nasal Spray Category Source: Proprietary research conduct

  42. Slide 42: Mucinex Will Also Capture Existing Nasal Spray Consumers

    Slide 42: Mucinex Will Also Capture Existing Nasal Spray Consumers

    Mucinex Will Also Capture Existing Nasal Spray Consumers 57% of current nasal spray users also expressed intent to purchase Mucinex Nasal Spray Current Afrin(r) users potentially the largest source Mucinex adds value with 50% more product per unit Higher Retail Revenue Higher Mucinex Retail Ring Sou

  43. Slide 43: Mucinex Nasal Sprays Market Opportunity

    Slide 43: Mucinex Nasal Sprays Market Opportunity

    Mucinex Nasal Sprays Market Opportunity Expands Mucinex franchise into additional respiratory segment High percentage of cough /cold category sufferers also use nasal sprays Year 1 projected to achieve 4% - 5% dollar share of nasal sprays market. Leading Medicated Nasal Spray Brands 2006 Dollar Shar

  44. Slide 44: Mucinex Nasal Sprays Marketing Support

    Slide 44: Mucinex Nasal Sprays Marketing Support

    Mucinex Nasal Sprays Marketing Support Dedicated TV commercial Consumer incentives to purchase both nasal spray and base Mucinex Professional efforts targeted to pharmacists

  45. Slide 45: Mr. Mucus Highlights

    Slide 45: Mr. Mucus Highlights

    Mr. Mucus Highlights "Here's Mucus" - Mucinex DM "Wrap" - Mucinex SE "Painter" - Children's Mucinex Mini-Melts

  46. Slide 46: Coming Soon: The New Adventures of Mr. Mucus

    Slide 46: Coming Soon: The New Adventures of Mr. Mucus

    Coming Soon: The New Adventures of Mr. Mucus

  47. Slide 47: I, RESPIRATORY

    Slide 47: I, RESPIRATORY

    I, RESPIRATORY THERAPEUTICS” (OI

  48. Slide 48: Delsym Core Equity

    Slide 48: Delsym Core Equity

    Delsym Core Equity Delsym = 12 hour Cough Relief

  49. Slide 49: Delsym Provides Unique Benefits

    Slide 49: Delsym Provides Unique Benefits

    Delsym Provides Unique Benefits The first and only OTC cough liquid that suppresses cough for 12 hours 4 hours longer than leading competitor Patented extended-release technology Great-tasting flavor

  50. Slide 50: Delsym acquisition and objectives

    Slide 50: Delsym acquisition and objectives

    Delsym Adams acquired Delsym in June 2006 from UCB to: Increase critical mass within respiratory market and develop a strategic foothold in OTC cough syrup segment Leverage our core competency: synergistic consumer and professional marketing Gain access to an additional proprietary delivery technolo

  51. Slide 51: Delsym Consumption Reached New High

    Slide 51: Delsym Consumption Reached New High

    Source: IRI U.S. FDMx, 52 weeks ended 2/25/07. *4 weeks ended 12/31/06. Adams Acquired Delsym(r) Professional Promotion Began Consumer Advertising Began Delsym Consumption Reached New High +70% VYA Achieved all-time consumption high of 18.9% at peak* ahead of Robitussin(r) DM 101

  52. Slide 52: Delsym

    Slide 52: Delsym

    Delsym SUPPRESSANT Delsym COUGH SUPPRESSANT Deisym COUGH SUPPRESSANT 12.3 HOUR Cough Reliet neisym y i RESPIRATORY Is 52

  53. Slide 53: Delsym Users Highly Loyal to Brand

    Slide 53: Delsym Users Highly Loyal to Brand

    Over 50% of Delsym users did not consider purchasing another brand to treat their cough 90% of purchasers plan to buy Delsym again Nearly 60% of users treated their cough with Delsym exclusively Delsym Users Highly Loyal to Brand Source: Proprietary on-line research conducted 12/06. High consumer sa

  54. Slide 54: Delsym Where We Are Now

    Slide 54: Delsym Where We Are Now

    Delsym Where We Are Now Fastest-growing cough syrup brand Highly productive franchise Single-flavor focused for Adults and Children's

  55. Slide 55: Delsym Where We Are Going

    Slide 55: Delsym Where We Are Going

    Delsym Where We Are Going Building awareness and trial (significant upside potential) Franchise expansion that delivers against the core benefit of 12 hour relief Improved shelf presence

  56. Slide 56: New Delsym Grape Flavor

    Slide 56: New Delsym Grape Flavor

    New Delsym Grape Flavor Grape line extension Flavor appeals to both children and adults Grape is #1 flavor in Children's segment with 39% of retail market* Available in both Adult 3 oz. and Children 3 oz. Same active ingredient and dosing as orange flavor * IRI, U.S. FDMx, 52 weeks ended 2/25/07.

  57. Slide 57: Delsym Grape Should Attract New Users

    Slide 57: Delsym Grape Should Attract New Users

    Delsym Grape Should Attract New Users New grape variety provides greater choice to consumers for whom flavor is a trial motivator Fills an important flavor gap in the franchise Total Delsym consumption is expected to grow 15% to 20% in FY08

  58. Slide 58: Delsym Marketing Support

    Slide 58: Delsym Marketing Support

    Delsym Marketing Support Dedicated TV commercial

  59. Slide 59: Fiscal 2007 New Products

    Slide 59: Fiscal 2007 New Products

    Fiscal 2007 New Products Fiscal 2007 Fiscal 2006

  60. Slide 60: Expansion Accelerates in FY08

    Slide 60: Expansion Accelerates in FY08

    Expansion Accelerates in FY08 Fiscal 2008

Source: SEC EDGAR · 8-K filed Apr 4, 2007

More decks from Adams Respiratory Therapeutics Inc